Product image of Glypvilo (Vildagliptin) supplied by GNH India

Glypvilo

Active Ingredient:
Vildagliptin
Origin:
EU

Glypvilo (Vildagliptin)

Glypvilo is a prescription oral medication whose active ingredient is vildagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor used in the management of type 2 diabetes mellitus. It is marketed in the European Union and is supplied as an oral dosage form, though specific strength information varies by country.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glypvilo is indicated for adults with type 2 diabetes mellitus when diet, exercise, and other oral agents do not provide adequate glycaemic control. It may be used as monotherapy or in combination with other antidiabetic drugs.

  • Improves fasting and post‑prandial blood glucose levels.
  • Can be combined with metformin for enhanced effect.
  • May be added to sulfonylureas when additional control is needed.
  • Used alongside basal insulin in patients requiring insulin support.
  • Considered when patients have contraindications to other oral agents.

Side Effects

Side effects of Glypvilo vary in frequency and severity. Common reactions are usually mild and transient, while serious events are rare but require medical attention.

Common

  • Upper respiratory tract infection symptoms.
  • Headache or mild dizziness.
  • Gastrointestinal discomfort such as nausea.
  • Mild skin rash or itching.

Serious

  • Severe hypersensitivity reactions, including angio‑edema.
  • Pancreatitis presenting with abdominal pain.
  • Significant hepatic enzyme elevations.
  • Acute kidney injury in susceptible individuals.
  • Persistent hypoglycaemia when combined with insulin or sulfonylureas.

Precautions & Warnings

Before starting Glypvilo, certain health considerations should be reviewed to minimise risk.

  • Assess renal function; dose adjustment may be needed in impairment.
  • Monitor liver enzymes periodically, especially in patients with hepatic disease.
  • Use caution in elderly patients due to increased sensitivity to side effects.
  • Evaluate for a history of pancreatitis before initiating therapy.
  • Discuss pregnancy and breastfeeding plans with a healthcare professional.
  • Review all concomitant medications to avoid potential interactions.
  • Advise patients to report any signs of severe skin reactions promptly.

Avoid Interactions

Glypvilo can interact with several drug classes, influencing its efficacy or safety profile.

Avoid

  • Strong CYP450 inhibitors that may increase vildagliptin plasma levels.
  • Concurrent use with other DPP‑4 inhibitors, which can lead to additive effects.
  • Medications known to cause pancreatitis, such as certain GLP‑1 receptor agonists.

Use with caution

  • Sulfonylureas or insulin, as the risk of hypoglycaemia may rise.
  • Diuretics that affect renal clearance, requiring monitoring of renal function.
  • NSAIDs that may impact kidney function, especially in patients with pre‑existing renal disease.
  • Anticoagulants, where close monitoring of coagulation parameters is advisable.

Frequently Asked Questions

Glypvilo inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which increases incretin hormone levels, enhancing glucose‑dependent insulin secretion and reducing glucagon release.

Glypvilo is generally prescribed when diet, exercise, and other oral agents do not achieve target glycaemic control; it may be used as initial therapy in some patients based on clinical judgment.

The safety of Glypvilo in pregnancy has not been established; women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatments with their healthcare provider.

Common side effects include upper respiratory tract infections, headache, mild nausea, and occasional skin rash or itching.

Renal function should be assessed before starting therapy and periodically thereafter; dose adjustments may be required for patients with moderate to severe renal impairment.

Yes, Glypvilo is frequently combined with metformin to improve glycaemic control, provided the patient tolerates both medications.

Symptoms such as swelling of the face or throat, difficulty breathing, or a widespread rash may signal a serious hypersensitivity reaction and require immediate medical attention.

Glypvilo alone has a low risk of hypoglycaemia, but the risk rises when it is used together with insulin or sulfonylureas.

Moderate alcohol consumption is not contraindicated, but excessive intake may affect blood glucose levels and should be discussed with a healthcare professional.

Baseline liver function tests are recommended before initiating therapy, with periodic monitoring thereafter, especially in patients with pre‑existing liver disease.

Elderly patients may be more sensitive to side effects; clinicians often start with the lowest effective dose and monitor response closely.

If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next scheduled dose; they should not double‑dose.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT